Natco Pharma Ltd has increased its proposed investment in US-based biotechnology firm eGenesis Inc to $16.7 million (around Rs 139 crore) from the earlier disclosed amount of $14 million.
Under the revised structure, NATCO Pharma (Canada) Inc will invest $13.7 million, while NATCO Pharma USA LLC will contribute $3 million, according to a regulatory filing.
The investment involves the purchase of convertible promissory notes carrying 8% annual compounded interest. No additional shares will be acquired at the time of completion, with the transaction expected to close by October 31.